Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade

PLoS ONE

Volumn 12, Issue 12, 2017, Pages

  Lin, Chih Ching ^a   Wu, Yu Te ^b,c   Yang, Wu Chang ^b,d   Tsai, Min Juei ^b,e   Liu, Jia Sin ^f   Yang, Chi Yu ^a,b   Li, Szu Yuan ^a,b   Ou, Shuo Ming ^a,b   Tarng, Der Cherng ^a,b   Hsu, Chih Cheng ^f,g,h  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Sungho Clinic   (Taiwan)

^d Landseed Hospital   (Taiwan)

^e Chang Hua Hospital   (Taiwan)

^f NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

^h MIN SHENG GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEMODIALYSIS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERKALEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PROTEINURIA; RENAL PROTECTION; VERY ELDERLY; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES;

EID: 85037663228     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0189126     Document Type: Article

References (22)

1. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12):861–9. Epub 2001/09/22. https://doi.org/10.1056/NEJMoa011161 PMID: 11565518.
2. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12):851–60. Epub 2001/09/22. https://doi.org/10.1056/NEJMoa011303 PMID: 11565517.
3. Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol. 2007; 18(6):1889–98. Epub 2007/05/15. https://doi.org/10.1681/ASN.2006121372 PMID: 17494885.
4. Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med. 2014; 174(3):347–54. Epub 2013/12/18. https://doi.org/10.1001/jamainternmed.2013.12700 PMID: 24343093.
5. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008; 148(1):30–48. Epub 2007/11/07. PMID: 17984482.
6. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372(9638):547–53. Epub 2008/08/19. https://doi.org/10.1016/S0140-6736(08)61236-2 PMID: 18707986.
7. Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012; 156(8):570–81. Epub 2012/04/18. PMID: 22508734.
8. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000; 57(5):1803–17. Epub 2000/05/03. https://doi.org/10.1046/j.1523-1755.2000.00031.x PMID: 10792600.
9. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013; 369(20):1892–903. Epub 2013/11/12. https://doi.org/10.1056/NEJMoa1303154 PMID: 24206457.
10. Kim MJ, Song JH, Suh JH, Lee SW, Kim GA. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy. Yonsei Med J. 2003; 44(3):463–72. Epub 2003/07/02. https://doi.org/10.3349/ymj.2003.44.3.463 PMID: 12833584.
11. Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, et al. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol. 2003; 60(5):318–26. Epub 2003/12/03. PMID: 14640237.
12. Shikata K, Makino H. Microinflammation in the pathogenesis of diabetic nephropathy. J Diabetes Investig. 2013; 4(2):142–9. Epub 2013/03/18. https://doi.org/10.1111/jdi.12050 PMID: 24843643.
13. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012; 367(23):2204–13. https://doi.org/10.1056/NEJMoa1208799 PMID: 23121378.
14. Li SY, Chen YT, Yang WC, Tarng DC, Lin CC, Yang CY, et al. Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease. BMC Nephrol. 2012; 13:89. Epub 2012/08/25. https://doi.org/10.1186/1471-2369-13-89 PMID: 22917002.
15. Chan KE, Ikizler TA, Gamboa JL, Yu C, Hakim RM, Brown NJ. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int. 2011; 80(9):978–85. Epub 2011/07/22. https://doi.org/10.1038/ki.2011.228 PMID: 21775975.
16. Gamboa JL, Pretorius M, Todd-Tzanetos DR, Luther JM, Yu C, Ikizler TA, et al. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J Am Soc Nephrol. 2012; 23(2):334–42. Epub 2011/12/14. https://doi.org/10.1681/ASN.2011030287 PMID: 22158433.
17. Gamboa JL, Pretorius M, Sprinkel KC, Brown NJ, Ikizler TA. Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis—a randomized cross-over study. BMC Nephrol. 2015; 16:167. Epub 2015/10/27. https://doi.org/10.1186/s12882-015-0162-x PMID: 26494370
18. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens. 2000; 18(1):89–95. Epub 2000/03/04. PMID: 10678548.
19. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009; 169(12):1156–62. Epub 2009/06/24. https://doi.org/10.1001/archinternmed.2009.132 PMID: 19546417
20. An JN, Lee JP, Jeon HJ, Kim do H, Oh YK, Kim YS, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care. 2012; 16(6):R225. Epub 2012/11/23. https://doi.org/10.1186/cc11872 PMID: 23171442
21. Uribarri J, Oh MS, Carroll HJ. Hyperkalemia in diabetes mellitus. J Diabet Complications. 1990; 4(1):3–7. Epub 1990/01/01. PMID: 2141843.
22. Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol. 2005; 162(10):1016–23. Epub 2005/09/30. https://doi.org/10.1093/aje/kwi307 PMID: 16192344.